Clinical, Social and Economic Impact Projects

Getting better Outcomes with Chimeric Antigen Receptor T-cell therapy (GO–CART): A BioCanRx Research Excelerator to Safely and Effectively Translate CAR-T Cell Therapy for Hematological Malignancies

 

Dr. Manoj Lalu, The Ottawa Hospital Research Institute, University of Ottawa
Approved January 17, 2016 | Project value $414,119 | 6 partners | $364,119 from BioCanRx

 

 
 

 
 

Translational Cancer Immunotherapeutics: Improving the Design, Analysis, and Reporting of Preclinical Studies

 

Dr. Dean Fergusson, The Ottawa Hospital Research Institute, University of Ottawa
Approved January 17, 2016 | Project value $196,093

 

 
 

 
 

TOWARDS RATIONAL DESIGN OF POLICIES AND PRACTICES TO ENABLE CLINICAL TRANSLATION OF NOVEL CANCER BIOTHERAPEUTICS IN CANADA

 

Dr. Tania Bubela, University of Alberta
Approved January 5, 2016 | Project value $396, 386 | 6 partners | $346, 386 from BioCanRx

 

 
 

 
 

IMPROVING THE QUALITY OF JUDGEMENT IN CANCER THERAPEUTICS DEVELOPMENT

 

Dr. Jonathan Kimmelman, McGill University
Approved January 5, 2016 | Project value $553, 856 | 1 partner | $538, 856 from BioCanRx